The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The exact way that these receptors are distributed over the surface of the T cells is still not completely understood, but the analyses by TU Wien show that previous ideas are no longer tenable.

It was previously thought that the T cell would concentrate the receptors at certain points in order to achieve the highest possible sensitivity. As a current publication by the biophysics research group at TU Wien shows, T cells are actually programmed to react as quickly as possible, and therefore their receptors are arranged at random. These results were made possible by close collaboration between the Medical University of Vienna (MUW) and the Max Planck Institute (MPI) of Biophysics in Göttingen. These new findings not only help to better understand the immune response, but are also key in developing new methods of medical treatment. These findings have now been published in the specialist journal Nature Immunology.

A needle in a haystack

"A T cell is a highly specific molecule detector," explains Prof. Gerhard Schütz, head of the biophysics research group at the Institute of Applied Physics at TU Wien. "Each T cell only reacts to a very specific molecule, and so we need many different T cells in our bodies." Each T cell carries many thousands of copies of the same receptor on its surface.

To trigger an immune reaction, the T cell still needs an important partner - the so-called antigen-presenting cell. The surfaces of these cells present many different molecules with the aid of special carrier proteins. Some of these molecules originate from endogenous structures and are harmless, but characteristic antigens of harmful intruders are also transported by the body on these antigen-presenting cells.

If the T cell comes into contact with one of these antigen-presenting cells, the search for a needle in a haystack begins. What happens if a molecule of the exact type for which the T cell is programmed, is found amongst the many hundreds of thousands of molecules that are on the surface of the antigen-presenting cell? "Imagine that the T cell has countless versions of the same key on its surface, and now has to quickly find out whether it fits any of the hundreds of thousands of locks on the antigen-presenting cell," explains Gerhard Schütz.

Speed counts

Controversially, it has been discussed how the T cells manage to react so extremely sensitively to a small amount of very specific antigens. A widely held theory is that a greater number of receptors on the T-cell surface are locally concentrated in clusters, and together the receptors then manage to more precisely dock with a specific antigen. When modern high-performance microscopic methods improved to the extent that images of these T-cell surfaces could be taken for the first time, this theory appeared to be confirmed. Irregular structures could be seen on the T-cell surfaces that were interpreted as receptor clusters.

But this conclusion was a little premature. "We examined the T cells very closely and focused all our efforts on improving the microscopic methods," says Gerhard Schütz. "What was previously thought to be clusters of several receptors is probably no more than an artefact; it's actually quite easy to image the same receptor molecule multiple times."

The analyses carried out at TU Wien have now suggested another theory: The receptors might well be distributed randomly over the T cell. That would also explain why the immune reaction happens so quickly. Regardless of how the antigen-presenting cell comes into contact with the T cell, the T cell always has a 'key' that fits the 'lock' at this location. If this is correct, the two cells do not lose any time getting into the right position, but instead the immune reaction can be triggered immediately.

"With this, we are working at the outer limits of what is possible with the most modern microscopic methods," says Gerhard Schütz. "It is an exciting time for immunology. We hope that, by better understanding the T-cell surface, we can make a contribution to understanding the first steps involved in identifying pathogens. We will then try to apply these findings together with our partners in immunotherapy."

Benedikt Rossboth, Andreas M Arnold, Haisen Ta, René Platzer, Florian Kellner, Johannes B Huppa, Mario Brameshuber, Florian Baumgart, Gerhard J Schütz.
TCRs are randomly distributed on the plasma membrane of resting antigen-experienced T cells.
Nature Immunology (2018). doi: 10.1038/s41590-018-0162-7.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...